Shen Lian Biomedical(SH:688098) Ge Long Hui A P P·2025-10-22 10:57Core Viewpoint - The company Shenyuan Biological (688098.SH) announced that its shareholder UBI plans to reduce its stake in the company to fund clinical trials and commercialization of its Alzheimer's peptide vaccine and to accelerate the construction of a manufacturing base in collaboration with Chinese partners [1] Group 1 - UBI intends to reduce its holdings by 4.1064 million shares through centralized bidding on the Shanghai Stock Exchange, which accounts for no more than 1.00% of the company's total shares [1] - Additionally, UBI plans to sell 8.2129 million shares through block trading, representing no more than 2.00% of the company's total shares [1] - The share reduction will be conducted at market prices, not lower than the company's initial public offering price [1]